Category Archives: Pharmaceuticals

Spotlight on three winning stocks from the past week and one absolute washout. But buy the dud first, then see what we think about the others.

1) Axsome Therapeutics Inc. (Nasdaq:AXSM) led advancing issues, skyrocketing 180% last week to $7.36. On Jan. 7, the NYC-based company reported that its lead drug candidate, AXS-05, hit its primary endpoint in… Read more »

UK’s Momentum Bio could help millions of hospital patients with first diagnostic test for blood infections that says whether or not to use antibiotics.

The News: Momentum Biosciences Ltd. (Cardiff UK) aims to pare back the unnecessary use of antimicrobial drugs in hospitals. To do this, it is developing molecular diagnostics that, within hours,… Read more »

Maat Pharma’s microbiome therapy shows early promise in cancer patients treatment. Are common gut bugs leading the charge to investment riches?

The News: A clinical trial run by MaaT Pharma SA (Lyon FRA) has shown that restoring the microbiome of patients undergoing chemotherapy has potential to improve the outcome of patients… Read more »

Health-sector investors hold breath as 2018 mercifully comes to a close; but what does 2019 portend? Anyone else cringe at prime-number years?

As investors stagger toward the New Year, adjusting their neck braces for one final lap of trading on December 31, there’s one big consolation for the recent, massive, daily twists… Read more »

This Dutch biotech startup is quietly developing a novel immune-cell approach for cancer. Can it muscle in on established rivals?

The News: Lava Therapeutics BV (Hertogenbosch NLD) is quietly developing a cancer immunotherapy that arms a rare type of immune cell called gamma delta T cells, Labiotech.eu reports. The company’s… Read more »

Moderna launches biggest biotech IPO ever, but shares immediately crash. Is this a buying opportunity?

The News: Moderna Therapeutics Inc. (Cambridge MA) watched its share price nosedive within hours of pulling off the biggest initial public offering in biotech history, a sign the company and its underwriters… Read more »

Tissue engineering and regenerative medicine starting to elbow its way into media coverage; watch out you cancer “miracle cures.”

The News: A group of researchers in Spain has developed a silk biomaterial that can increase the survival of transplanted stem cells into the brain, improving recovery after a stroke… Read more »

US IPOs not done yet for 2018 as two foreigners pick Nasdaq for their maiden launch.

The News: Last week, Taiwan Liposome Co. Ltd. (TLC), which is developing lipid formulations of approved drugs for pain and eye disease, raised $22 million by offering 3.75 million ADSs… Read more »

Europe frets over waning IPO biotech scene while US pricings and new registrations keep chugging along.

The News: Over the last two weeks, several biotech companies in Europe have decided to postpone IPOs on the stock markets there prompting speculation that biotech stocks are underperforming, according… Read more »

England’s biotech startup Sitryx out of the blocks with new I/O program. Stakes are high as Europe’s science contending with US for top global developers.

The News: Sitryx Therapeutics Ltd. (London) has launched with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising new area of research…. Read more »